Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
Uganda tells ARIPO: No more patents for pharmaceuticals
Uganda has notified the African Regional Intellectual Property Organisation (ARIPO) that pharmaceutical inventions are not eligible for patentability in the country, Managing IP reported.
With...
Corbyn’s Compulsory Licenses. Will they work?
On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...
Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
Drug Price Transparency Calls Move from South Africa to World Health Assembly
by Katrina Perehudoff and Jennifer Sellin
Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...
Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...
“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...
WHO Fair Pricing Forum: Watching for Drug Industry Accountability
by Katrina Perehudoff and Jennifer Sellin
Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
Faced with unreasonable medicines prices, the Netherlands introduces pharmacy exemption in patent law.
On 1 February 2019, article 53(3), second sentence of the Dutch Patent Act 1995 came into force introducing a patent exemption for the preparation...
Cystic Fibrosis Medicines Wars in Europe
Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...